SHPG : Summary for Shire plc - American Depositary - Yahoo Finance

U.S. Markets closed

Shire plc (SHPG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
174.80+3.82 (+2.23%)
At close: 4:00 PM EST
People also watch:
JAZZALXNBMRNMNKICPT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close170.98
Open174.50
Bid148.01 x 200
Ask194.72 x 100
Day's Range173.06 - 175.50
52 Week Range147.60 - 210.33
Volume948,613
Avg. Volume1,308,496
Market Cap54.38B
Beta1.62
PE Ratio (TTM)267.28
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.80 (0.46%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • InPlay from Briefing.com
    Briefing.com8 hours ago

    InPlay from Briefing.com

    InPlay from Briefing.com

  • PR Newswire8 hours ago

    Shire Reports on Four Decades of Real-World Safety Experience With FEIBA®

    Shire plc (LSE: SHP; NASDAQ: SHPG), the leading biotechnology company focused on serving individuals with rare diseases, is presenting an update on its safety database describing 40 years of real-world experience with the bypassing agent FEIBA [Anti-Inhibitor Coagulant Complex]. Shire also revealed new in vitro data showing the potential for excessive thrombin generation when combining an investigational procoagulant bispecific antibody and bypass therapy for breakthrough bleeds. Recently, concerns have emerged related to the use of an investigational non-factor product when combined with marketed bypassing agents for hemophilia patients with inhibitors.

  • Shire Loses Ground To Allergan In Thanksgiving Week Dry-Eye Scripts
    Investor's Business Daily9 hours ago

    Shire Loses Ground To Allergan In Thanksgiving Week Dry-Eye Scripts

    Thanksgiving week saw Shire's Xiidra lose some ground to rival Allergan in the dry-eye market, RBC says.